详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities

134| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Gynaecological Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China [2]National Clinical Research Centre for Obstetrics and Gynaecology,Cancer Biology Research Centre (Key Laboratory of the Ministry of Education),Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China

出处：

DOI：

ISSN：

关键词： ovarian cancer immune checkpoint inhibitors PD-1/PD-L1 blockade drug resistance

摘要：

Immune checkpoint inhibitors (ICIs) have revolutionized treatment in oncology. Antibodies against PD-1/PD-L1 and ICI-based combinations are under clinical investigations in multiple cancers, including ovarian cancer. However, the success of ICIs has not materialized in ovarian cancer, which remains one of the few malignancies where ICIs exhibit modest efficacy as either monotherapy or combination therapy. In this review, we summarize completed and ongoing clinical trials of PD-1/PD-L1 blockade in ovarian cancer, categorize the underlying mechanisms of resistance emergence, and introduce candidate approaches to rewire the tumor microenvironment (TME) to potentiate anti-PD-1/PD-L1 antibodies.Copyright © 2023. Published by Elsevier Ltd.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版中科院分区表Review为是的期刊

：

大类 | 2 区医学

小类 | 2 区药学

最新[2025]版

：

大类 | 2 区医学

小类 | 2 区药学

JCR分区：

出版当年[2021]版：

Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY

影响因子： 6.5 最新[2023版] 7.3 最新五年平均 8.369 出版当年[2021版] 9.193 出版当年五年平均 7.851 出版前一年[2020版] 7.4 出版后一年[2022版]

第一作者：

第一作者单位： [1]Department of Gynaecological Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China [2]National Clinical Research Centre for Obstetrics and Gynaecology,Cancer Biology Research Centre (Key Laboratory of the Ministry of Education),Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Gynaecological Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China [2]National Clinical Research Centre for Obstetrics and Gynaecology,Cancer Biology Research Centre (Key Laboratory of the Ministry of Education),Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Combination strategies with PD-1/PD-L1 blockade: current advances and future directions [2]Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade [3]Macrophages facilitate tumor cell PD-L1 expression via an IL-1 beta-centered loop to attenuate immune checkpoint blockade [4]Immune Checkpoint Inhibitors Related to Cardiotoxicity [5]Immune checkpoint inhibitors in the treatment of virus-associated cancers [6]Fever of unknown origin associated with immune checkpoint inhibitors [7]Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors [8]Gut microbiome modulates efficacy of immune checkpoint inhibitors [9]The efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer [10]Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors